Core Viewpoint - Ruijin Hainan Hospital is leveraging institutional innovation to establish itself as a new highland for international medical services in the Hainan Free Trade Port, aiming to connect global medical resources with local patients [3][4][5]. Group 1: Institutional Innovation and Medical Services - Ruijin Hainan Hospital is a key project approved by the Hainan provincial government, officially starting operations in December 2021 and achieving full medical process integration by March 2022 [3][4]. - The hospital has successfully implemented 186 special drug and medical device projects, benefiting over 26,800 patients, significantly reducing the economic burden on patients by negotiating lower prices for these products [5][6]. Group 2: Real-World Research and Clinical Advancements - The hospital is conducting high-quality real-world data research to accelerate the registration and market entry of international innovative drugs and devices in China, exemplified by the rapid approval of Isatuximab injection for multiple myeloma patients [6][7]. - Innovative mechanisms have been established, including a dedicated technical expansion department and a patient management platform, to enhance the accessibility of quality medical resources [6][9]. Group 3: Talent Development and Cultural Integration - The hospital is focusing on a "transfer and cultivate" approach to talent development, aiming to instill the spirit of Ruijin Hospital in Hainan while building a sustainable local talent pool [7][8]. - Collaborative initiatives with Shanghai Jiao Tong University and other institutions are being pursued to provide local talents with international learning and research opportunities [8]. Group 4: Regional Medical Ecosystem and Internationalization - Ruijin Hainan Hospital is enhancing the regional medical ecosystem through platform sharing and resource integration, collaborating with local hospitals to provide high-quality medical services [9]. - The hospital is actively pursuing international cooperation, including partnerships with Southeast Asian medical institutions and exploring international insurance models to improve service standards [9].

Core Insights - The Ninth Hu-Lu Cardiovascular Disease Expert Forum and several other significant academic meetings were held in Rizhao, focusing on advancements in cardiovascular disease treatment and collaboration among experts in the field [1][5][9]. Group 1: Event Overview - The event included multiple important academic activities such as the Hu-Lu Cardiovascular Disease Expert Forum, the 21st CTOCC meeting, and the first session of the CCI Innovation Academy, aimed at integrating high-quality resources and enhancing efficiency in cardiovascular medicine [9][10]. - The forum has evolved over nine years into a prestigious academic event, emphasizing the core values of inheritance, innovation, cooperation, and talent cultivation in the medical field [5][7]. Group 2: Expert Contributions - Key experts, including Professor Ge Junbo and Professor Huo Yong, highlighted the importance of multi-conference collaboration in advancing cardiovascular medicine and fostering regional cooperation [7][9]. - The event showcased successful demonstrations of complex chronic total occlusion (CTO) surgeries, emphasizing the application of innovative techniques and the sharing of clinical experiences among top experts [12][14]. Group 3: Institutional Achievements - The Qingdao University Affiliated Rizhao Hospital has completed over 20,000 surgeries in seven years, establishing itself as a trusted institution in the region and achieving significant technical breakthroughs [9][16]. - The hospital has introduced numerous new techniques, including several firsts in Shandong province, reinforcing its commitment to advancing cardiovascular care and ensuring public health [16].